Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression

[1]  W. Muller,et al.  Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis , 2011, Proceedings of the National Academy of Sciences.

[2]  R. Cardiff,et al.  The Pathology of EMT in Mouse Mammary Tumorigenesis , 2010, Journal of Mammary Gland Biology and Neoplasia.

[3]  B. Schaffhausen,et al.  Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen , 2009, Microbiology and Molecular Biology Reviews.

[4]  Harold Varmus,et al.  Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.

[5]  H. Varmus,et al.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras , 2008, Proceedings of the National Academy of Sciences.

[6]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[7]  R. Cardiff,et al.  Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression , 2007, Proceedings of the National Academy of Sciences.

[8]  T. Roberts,et al.  The p110α Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation , 2007, Journal of Virology.

[9]  W. Muller,et al.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.

[10]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[11]  Robert D Cardiff,et al.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.

[12]  Robert B Boxer,et al.  A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[14]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[15]  J. Ashwell,et al.  Thymus-derived glucocorticoids set the thresholds for thymocyte selection by inhibiting TCR-mediated thymocyte activation. , 1999, Journal of immunology.

[16]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[17]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[18]  G. Mills,et al.  Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms , 2011 .

[19]  R. Cardiff,et al.  Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene. , 2006, The American journal of pathology.

[20]  Philippe Soriano.  Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.